InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 16,500 shares, an increase of 26.9% from the May 15th total of 13,000 shares. Based on an average trading volume of 12,900 shares, the short-interest ratio is currently 1.3 days. Approximately 0.1% of the company's stock are sold short.
Hedge Funds Weigh In On InterCure
An institutional investor recently bought a new position in InterCure stock. Moore Capital Management LP acquired a new position in InterCure Ltd. (NASDAQ:INCR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 97,273 shares of the company's stock, valued at approximately $156,000. Moore Capital Management LP owned approximately 0.21% of InterCure at the end of the most recent quarter. Institutional investors and hedge funds own 8.34% of the company's stock.
InterCure Stock Up 0.7%
InterCure stock opened at $1.50 on Wednesday. The company's fifty day simple moving average is $1.49 and its 200-day simple moving average is $1.54. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.18 and a current ratio of 1.73. InterCure has a 12 month low of $1.17 and a 12 month high of $2.62.
About InterCure
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
